Aranelle®
(norethindrone and ethinyl estradiol tablets, USP)
28 Day Regimen
9066
Rx only
Iss. 7/2010
11001692
Patients should be counseled that this product does not protect against HIV infection (AIDS) and other sexually transmitted diseases.
Cigarette smoking increases the risk of serious cardiovascular side effects from oral contraceptive use. This risk increases with age and with heavy smoking (15 or more cigarettes per day) and is quite marked in women over 35 years of age. Women who use oral contraceptives should be strongly advised not to smoke.
DESCRIPTION
Aranelle® 28-Day Regimen (norethindrone and ethinyl estradiol tablets, USP) provides a continuous oral contraceptive regimen of 7 light yellow tablets, 9 white tablets, 5 more light yellow tablets, and then 7 peach tablets. Each light yellow tablet contains norethindrone 0.5 mg and ethinyl estradiol 0.035 mg, each white tablet contains norethindrone 1 mg and ethinyl estradiol 0.035 mg, and each peach tablet contains inert ingredients.
Norethindrone is a potent progestational agent with the chemical name 17-Hydroxy-19-nor-17α-pregn-4-en-20-yn-3-one. Ethinyl estradiol is an estrogen with the chemical name 19-Nor-17α-pregna-1,3,5(10)-trien-20-yne-3,17-diol. Their structural formulae follow
Norethindrone
Ethinyl Estradiol
The light yellow tablet contains the following inactive ingredients, D&C yellow no. 10 aluminum lake, lactose monohydrate, magnesium stearate, and pregelatinized starch.
The white tablet contains the following inactive ingredients, lactose monohydrate, magnesium stearate, and pregelatinized starch.
The inactive peach tablets contain the following inactive ingredients, anhydrous lactose, FD&C yellow no. 6 aluminum lake, magnesium stearate, microcrystalline cellulose, and pregelatinized starch.
CLINICAL PHARMACOLOGY
Combination oral contraceptives act by suppression of gonadotropins. Although the primary mechanism of this action is inhibition of ovulation, other alterations include changes in the cervical mucus (which increase the difficulty of sperm entry into the uterus) and the endometrium (which may reduce the likelihood of implantation).
INDICATIONS AND USAGE
Oral contraceptives are indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception.
Oral contraceptive products which contain 50 mcg of estrogen, should not be used unless medically indicated.
Oral contraceptives are highly effective. Table I lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception.1 The efficacy of these contraceptive methods, except sterilization, depends upon the reliability with which they are used. Correct and consistent use of methods can result in lower failure rates.
TABLE I PERCENTAGE OF WOMEN EXPERIENCING AN UNINTENDED PREGNANCY DURING THE FIRST YEAR OF TYPICAL USE AND THE FIRST YEAR OF PERFECT USE OF CONTRACEPTION AND THE PERCENTAGE CONTINUING USE AT THE END OF THE FIRST YEAR. UNITED STATES.
Source: Trussell J, Contraceptive Efficacy Table from Hatcher RA, Trussell J, Stewart F, Cates W, Stewart GK, Kowal D, Guest F, Contraceptive Technology: Seventeenth Revised Edition. New York, NY: Irvington Publishers, 1998. |
|
|
% of Women Experiencing an
Unintended Pregnancy
within the First Year of Use |
% of Women Continuing Use at One Year* |
Method
(1) |
Typical Use†
(2) |
Perfect Use‡
(3) |
(4) |
Chance§ |
85 |
85 |
|
Spermicides¶ |
26 |
6 |
40 |
Periodic abstinence |
25 |
|
63 |
Calendar |
|
9 |
|
Ovulation Method |
|
3 |
|
Sympto-Thermal# |
|
2 |
|
Post-Ovulation |
|
1 |
|
Withdrawal |
19 |
4 |
|
|